Notice of AGM and Notice of Results

RNS Number : 2789H

Abingdon Health PLC

23 November 2022

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

Notice of Annual General Meeting and Notice of Results

York, U.K. 23 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces that its Annual General Meeting ('AGM') will be held on Monday 19 December at 9.30 a.m. at the offices of Abingdon Health, York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom. Furthermore, the Company will be releasing its preliminary results for the year ended 30 June 2022 on 24 November 2022.

The notice convening the AGM will be sent to shareholders today and is available on the Company's website www.abingdonhealth.com .

Enquiries:

Abingdon Health plc		www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer		Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Nominated Adviser)		Tel: [phone]
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Phillip Marriage Alice Woodings	Mob: [phone] [phone]

About Abingdon Health plc

Abingdon Health is a world leading  developer and manufacturer of high-quality lateral flow rapid tests  across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx^®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit:  www.abingdonhealth.com

 

END

 

 

NOAFFFLLLTLFFIF